Physician profile
Andrew Waligora
NPI 1699731521
$984.96
in general payments reported to CMS, 2019-2025
19 companies · $80.26 in 2025
The $80.26 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $106 · 2021: $25.11 · 2022: $110 · 2023: $105 · 2024: $185 · 2025: $80.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.78 |
| Education | $105.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.05 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $145.52 | 2019-2025 | Wegovy, Ozempic |
| Zimmer Biomet Holdings, INC. | $118.08 | 2019 | |
| Travere Therapeutics, INC. | $101.03 | 2022-2025 | Thiola, Filspari |
| Otsuka America Pharmaceutical, INC. | $80.52 | 2019-2020 | |
| Lilly USA, LLC | $49.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $41.96 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $40.64 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.71 | 2022-2023 | |
| Amgen INC. | $36.12 | 2023-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $28.91 | 2019 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Kyowa Kirin, INC. | $18.54 | 2024 | Crysvita |
| Allergan, INC. | $17.75 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.16 | 2019 | |
| Ardelyx, INC. | $15.35 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $15.23 | 2019 | |
| Lundbeck LLC | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Waligora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.